ClinicalTrials.gg
CompletedNCT04448756Updated Jun 6, 2022Results posted

Study of M5049 in Participants With COVID-19 Pneumonia (ANEMONE)

A Phase 2 interventional study of M5049 and M5049 in Coronavirus Disease 2019, sponsored by EMD Serono Research & Development Institute, Inc.. Completed at 21 sites in 3 countries. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2022-06-06.

Sponsored by EMD Serono Research & Development Institute, Inc. (part of Merck KGaA, Darmstadt, Germany) · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
149
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 317 studies in COVID-19 with a site in Brazil — 20 open to participants now, 28 under way, 9 of them phase 3. COVID-19 · Brazil.

Enrollment
154th of 263
149 · median 205
Started
2020
with 152 others
Phase 2
56 of 317
2 open now
Registered
72nd of 317
by date

Among the 317 studies in COVID-19 with a site in Brazil, this one is the 154th largest by enrollment of the 263 interventional ones that give a count, is one of 153 that started in 2020, is one of 56 in phase 2, and was the 72nd registered.

COVID-19

7,994 studies on the registry are indexed under COVID-19; 467 are open to participants now.

Browse COVID-19 studies →

Open to participants now

20 of the 317 studies in COVID-19 with a site in Brazil are open now. Recruiting first, the newest first:

15 more — sign in →

All 20 open studies →

A study can be open while its sites in Brazil have not opened yet or have stopped. Only those recruiting at a site in Brazil →

Who these studies take

Of the 356 COVID-19 studies recruiting now, 206 (58%) set no upper age limit and 83 (23%) stop at 75 or younger; 91 take children under 18; 135 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 317 studies in COVID-19 with a site in Brazil, or all of them as a file.
02

Study summary

The study will evaluate the safety and efficacy of orally-administered M5049 in Coronavirus disease 2019 (COVID-19) pneumonia participants who are hospitalized but not on mechanical ventilation.

03

Conditions studied

  • Coronavirus Disease 2019

Browse trials for

Keywords

  • COVID-19
  • Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2)
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participant provides signed prior to the initiation of any study assessments
  • Has laboratory-confirmed SARS-CoV-2 Infection as determined by nucleic acid amplification test, polymerase chain reaction, antigen test or other commercial or public health assay (based on locally acceptable accepted guidelines) in a sample collected less than (\<)10 days prior to randomization
  • Has chest imaging consistent with COVID-19 pneumonia (as per locally accepted guidelines) If chest imaging is not available during Screening, please discuss with Medical Monitor or designee regarding evidence of probable COVID-19 pneumonia for study participant eligibility
  • Not on mechanical ventilation or ECMO
  • Has an SpO2 less than (\<) 94 percent in room air And able to maintain a partial pressure of oxygen (PaO2)/fraction of inspired oxygen (FiO2) greater than or equal to (>=) 150 (Or equivalent SpO2/FiO2 >=190) with a maximum FiO2 0.4 if participant is on chronic low oxygen therapy (less than or equal to 2 Liter), assess their current baseline oxygen requirements for eligibility
  • Requires hospitalization
  • Other protocol defined inclusion criteria may apply

Exclusion criteria

Exclusion Criteria:

  • Any condition that could interfere with the study objectives, conduct or evaluation in the opinion of the Investigator or Sponsor or designee
  • Significantly uncontrolled medical illness (eg, cardiovascular disease, hypertension, diabetes mellitus, obstructive lung disease, neurological associated with seizures (example: cerebrovascular accident/stroke, acute brain infection, traumatic brain injury, progressive brain disease, congenital brain disease or neuropsychiatric disorder)
  • Known active infection other than COVID-19
  • Pregnancy or Breastfeeding
  • Other protocol defined exclusion criteria may apply
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
149 participants (actual)

Study arms

  • Experimental
    M5049 50 mg

    Drug: M5049

  • Experimental
    M5049 100 mg

    Drug: M5049

  • Placebo comparator
    Placebo

    Drug: Placebo

Interventions

  • DrugM5049

    Participants received M5049 50 milligram (mg) orally twice daily for 14 days.

  • DrugM5049

    Participants received M5049 100 mg orally twice daily for 14 days.

  • DrugPlacebo

    Participants received placebo tablets matched to M5049 daily for 14 days.

06

What researchers measure

Primary outcomes

  1. Time to Recovery

    Time to recovery was defined as the time from first dose (Day 1) to first occurrence of World Health Organization (WHO) 9-point ordinal scale 3 or less. The scoring is assessed with the following ordinal scale: 0. Uninfected: no clinical or virological evidence of infection; 1. Ambulatory: no limitation of activities; 2. Ambulatory: limitation of activities; 3. Hospitalized, mild disease: hospitalized, no oxygen therapy; 4. Hospitalized, mild disease: oxygen by mask or nasal prongs; 5. Hospitalized, severe disease: noninvasive ventilation or high-flow oxygen; 6. Hospitalized, severe disease: intubation and mechanical ventilation; 7. Hospitalized, severe disease: ventilation plus additional organ support for example: vasopressors or Extracorporeal membrane oxygenation (ECMO); 8. Death.

    Time frame: Day 1 through Day 28

  2. Number of Participants With Treatment-Emergent Adverse Events (TEAEs), Adverse Events of Special Interests (AESIs), TEAEs Leading to Treatment Discontinuation and Serious TEAEs (SAEs) According to NCI-CTCAE Version 5.0

    Adverse Event (AE) was defined any untoward medical occurrence in a participant administered with a study drug, which does not necessarily had a causal relationship with this treatment. Serious AE was defined AE that resulted in any of the following outcomes: death; life threatening; persistent/significant disability/incapacity; initial/prolonged inpatient hospitalization; congenital anomaly/birth defect. TEAEs: TEAEs was defined as events with onset date or worsening during the on treatment period. TEAEs included serious TEAEs and non-serious TEAEs.

    Time frame: Day 1 through Day 60

  3. Number of Participants With Clinically Significant Changes From Baseline in Laboratory Parameters

    Laboratory investigation included hematology and biochemistry. The number of participants with clinically significant changes from baseline in laboratory parameters were reported. Clinical significance was determined by the investigator.

    Time frame: Day 1 through Day 28

  4. Number of Participants With Clinically Significant Changes From Baseline in 12-Lead Electrocardiogram (ECG) Measurements

    12-lead ECG recordings included rhythm, heart rate (as measured by RR interval), PR interval, QRS duration, and QT interval. 12-lead ECG recordings were obtained after the participants have rested for at least 10 minutes in semisupine position. Clinical significance was determined by the investigator. The number of participants with clinically significant changes from baseline in 12-lead ECG findings were reported.

    Time frame: Day 1 through Day 28

Secondary outcomes

  1. Percentage of Participants Alive and Not Requiring Supplemental Oxygenation

    The percentage of participants who were alive and did not require supplemental oxygenation or ventilatory support (including noninvasive or mechanical ventilation and Extra Corporeal Membrane Oxygenation \[ECMO\]) reported.

    Time frame: Day 3, Day 7, Day 14, Day 21 and Day 28

  2. Number of Participants in Each Clinical Status Category Based on 9-Point Ordinal Scale

    Clinical status was based on data collected on the 'Ordinal Scale for Clinical Status and is assessed with the following ordinal scale: 0. Uninfected: no clinical or virological evidence of infection; 1. Ambulatory: no limitation of activities; 2. Ambulatory: limitation of activities; 3. Hospitalized, mild disease: hospitalized, no oxygen therapy; 4. Hospitalized, mild disease: oxygen by mask or nasal prongs; 5. Hospitalized, severe disease: noninvasive ventilation or high-flow oxygen; 6. Hospitalized, severe disease: intubation and mechanical ventilation; 7. Hospitalized, severe disease: ventilation plus additional organ support for example: vasopressors or ECMO; 8. Death.

    Time frame: Baseline, Day 2, Day 3, Day 4, Day 5, Day 7, Day 10, Day 14, Day 21, Day 28, Day 44, Day 60

  3. Time to Reach Peripheral Capillary Oxygen Saturation (SpO2) Greater Than or Equal to 94 Percent for at Least 24 Hours in Room Air

    SpO2 is an estimate of the amount of oxygen in the blood. It is the percentage of hemoglobin containing oxygen compared to the total amount of hemoglobin in the blood (that is, oxygenated hemoglobin versus oxygenated and non-oxygenated hemoglobin). SpO2 measured by pulse oximetry. The time to SPO2 greater than or equal to (\>=) 94 percent (%) sustained for at least 24 hours in room air is reported in days.

    Time frame: Day 1 through Day 28

  4. Percentage of Participants With All-Cause Mortality

    Percentage of Participants who died for any reason reported.

    Time frame: Day 1 through Day 60

  5. Time to Intensive Care Unit (ICU) Admission

    Time to ICU admission was defined as the time from first dose (Day 1) to the date/time of ICU admission, or death, whichever occurs first, in days. Event-free survival function for time to event (ICU admission or death) estimated via Kaplan-Meier method.

    Time frame: Day 1 through Day 28

  6. Time to Non-Invasive Mechanical Ventilation

    Time to non-invasive mechanical ventilation was defined as the time from first dose (Day 1) to the date/time of clinical status \>= 5, in days. Event-free survival function for time to event (Non-invasive mechanical ventilation or death) estimated via Kaplan-Meier method. Clinical status was based on data collected on the 'Ordinal Scale for Clinical Status and is assessed with the following ordinal scale: 0. Uninfected: no clinical or virological evidence of infection; 1. Ambulatory: no limitation of activities; 2. Ambulatory: limitation of activities; 3. Hospitalized, mild disease: hospitalized, no oxygen therapy; 4. Hospitalized, mild disease: oxygen by mask or nasal prongs; 5. Hospitalized, severe disease: noninvasive ventilation or high-flow oxygen; 6. Hospitalized, severe disease: intubation and mechanical ventilation; 7. Hospitalized, severe disease: ventilation plus additional organ support for example: vasopressors, and ECMO; 8. Death

    Time frame: Day 1 through Day 28

  7. Time to Invasive Mechanical Ventilation

    Time to invasive mechanical ventilation was defined as the time from first dose (Day 1) to the date/time of clinical status \>= 6, in days. Event-free survival function for time to event (invasive mechanical ventilation or death) estimated via Kaplan-Meier method. Clinical status was based on data collected on the 'Ordinal Scale for Clinical Status and is assessed with the following ordinal scale: 0. Uninfected: no clinical or virological evidence of infection; 1. Ambulatory: no limitation of activities; 2. Ambulatory: limitation of activities; 3. Hospitalized, mild disease: hospitalized, no oxygen therapy; 4. Hospitalized, mild disease: oxygen by mask or nasal prongs; 5. Hospitalized, severe disease: noninvasive ventilation or high-flow oxygen; 6. Hospitalized, severe disease: intubation and mechanical ventilation; 7. Hospitalized, severe disease: ventilation plus additional organ support for example: vasopressors, and ECMO; 8. Death.

    Time frame: Day 1 through Day 28

  8. Total Length of Stay in Intensive Care Unit (ICU)

    Total days in the ICU was defined as the sum, for all ICU admissions, of the time from ICU admission to the date of ICU discharge, in days.

    Time frame: Day 1 through Day 60

  9. Total Length of Hospitalization Stay

    Total days in the hospital was defined as the sum, for all hospitalization events, of the time from first dose to the date of hospital discharge in days.

    Time frame: Day 1 through Day 60

  10. Time to Hospital Discharge

    The time to hospital discharge, defined as the time from first dose (Day 1) to the date of first hospitalization discharge, in days.

    Time frame: Day 1 through Day 60

  11. Percent Change From Baseline in Inflammatory Biomarkers Over Time

    C-Reactive Protein, D-Dimer and Ferritin inflammatory biomarkers were analyzed for this study. Percent Change From Baseline in Inflammatory Biomarkers Over Time were reported here.

    Time frame: Baseline, Day 3, Day7, Day 10, Day 14 and Day 28

  12. Percent Change From Baseline in Serum Cytokine Biomarkers

    Interleukin 6 and Interleukin 8 serum cytokine biomarkers were analyzed. Percent Change From Baseline in Serum Cytokine Biomarkers were reported.

    Time frame: Baseline, Day 3, Day7, Day 14 and Day 28

  13. Percentage of Participants With Relapse

    Relapse refers to rehospitalization due to worsening oxygenation, with either a positive result of any respiratory pathogenic nucleic acid test, or worsening lesions on chest imaging.

    Time frame: Day 5 through Day 60

  14. Percentage of Participants Who Are Re-Hospitalized

    Percentage or participants who are re-hospitalized due to coronavirus disease 2019 (Covid-19) complications were reported.

    Time frame: Day 5 through Day 60

07

Results

Posted Jun 6, 2022

Participant flow

Overall, 200 participants were screened for this study. Of which, 149 participants were randomized into the study.

Participant flow — Overall Study
MilestonePlaceboM5049 50 Milligram (mg)M5049 100 mg
Started495446
Completed464945
Not completed351
Withdrew: Adverse event010
Withdrew: Participant unable to attend day 60 visit100
Withdrew: Withdrawal by subject031
Withdrew: Death210

Outcome measures

PrimaryTime to Recovery

Time to recovery was defined as the time from first dose (Day 1) to first occurrence of World Health Organization (WHO) 9-point ordinal scale 3 or less. The scoring is assessed with the following ordinal scale: 0. Uninfected: no clinical or virological evidence of infection; 1. Ambulatory: no limitation of activities; 2. Ambulatory: limitation of activities; 3. Hospitalized, mild disease: hospitalized, no oxygen therapy; 4. Hospitalized, mild disease: oxygen by mask or nasal prongs; 5. Hospitalized, severe disease: noninvasive ventilation or high-flow oxygen; 6. Hospitalized, severe disease: intubation and mechanical ventilation; 7. Hospitalized, severe disease: ventilation plus additional organ support for example: vasopressors or Extracorporeal membrane oxygenation (ECMO); 8. Death.

Time frame:
Day 1 through Day 28
Reported as:
Median · Days
Time to Recovery
DaysPlaceboM5049 50 Milligram (mg)M5049 100 mg
Time to Recovery3.4 (2.7 to 4.9)3.7 (2.6 to 4.0)3.9 (2.0 to 4.8)
PrimaryNumber of Participants With Treatment-Emergent Adverse Events (TEAEs), Adverse Events of Special Interests (AESIs), TEAEs Leading to Treatment Discontinuation and Serious TEAEs (SAEs) According to NCI-CTCAE Version 5.0

Adverse Event (AE) was defined any untoward medical occurrence in a participant administered with a study drug, which does not necessarily had a causal relationship with this treatment. Serious AE was defined AE that resulted in any of the following outcomes: death; life threatening; persistent/significant disability/incapacity; initial/prolonged inpatient hospitalization; congenital anomaly/birth defect. TEAEs: TEAEs was defined as events with onset date or worsening during the on treatment period. TEAEs included serious TEAEs and non-serious TEAEs.

Time frame:
Day 1 through Day 60
Reported as:
Count of participants · Participants
Number of Participants With Treatment-Emergent Adverse Events (TEAEs), Adverse Events of Special Interests (AESIs), TEAEs Leading to Treatment Discontinuation and Serious TEAEs (SAEs) According to NCI-CTCAE Version 5.0
ParticipantsPlaceboM5049 50 Milligram (mg)M5049 100 mg
Participants with any TEAE283426
Participants with any AESIs220
Participants with TEAEs leading to discontinuation441
Participants with Serious TEAEs951
PrimaryNumber of Participants With Clinically Significant Changes From Baseline in Laboratory Parameters

Laboratory investigation included hematology and biochemistry. The number of participants with clinically significant changes from baseline in laboratory parameters were reported. Clinical significance was determined by the investigator.

Time frame:
Day 1 through Day 28
Reported as:
Count of participants · Participants
Number of Participants With Clinically Significant Changes From Baseline in Laboratory Parameters
ParticipantsPlaceboM5049 50 Milligram (mg)M5049 100 mg
Number of Participants With Clinically Significant Changes From Baseline in Laboratory Parameters000
PrimaryNumber of Participants With Clinically Significant Changes From Baseline in 12-Lead Electrocardiogram (ECG) Measurements

12-lead ECG recordings included rhythm, heart rate (as measured by RR interval), PR interval, QRS duration, and QT interval. 12-lead ECG recordings were obtained after the participants have rested for at least 10 minutes in semisupine position. Clinical significance was determined by the investigator. The number of participants with clinically significant changes from baseline in 12-lead ECG findings were reported.

Time frame:
Day 1 through Day 28
Reported as:
Count of participants · Participants
Number of Participants With Clinically Significant Changes From Baseline in 12-Lead Electrocardiogram (ECG) Measurements
ParticipantsPlaceboM5049 50 Milligram (mg)M5049 100 mg
Number of Participants With Clinically Significant Changes From Baseline in 12-Lead Electrocardiogram (ECG) Measurements100
SecondaryPercentage of Participants Alive and Not Requiring Supplemental Oxygenation

The percentage of participants who were alive and did not require supplemental oxygenation or ventilatory support (including noninvasive or mechanical ventilation and Extra Corporeal Membrane Oxygenation \[ECMO\]) reported.

Time frame:
Day 3, Day 7, Day 14, Day 21 and Day 28
Reported as:
Number · Percentage of participants
Percentage of Participants Alive and Not Requiring Supplemental Oxygenation
Percentage of participantsPlaceboM5049 50 Milligram (mg)M5049 100 mg
At Day 330.6 (19.5 to 44.5)27.5 (17.1 to 40.9)38.6 (25.7 to 53.4)
At Day 776.6 (62.8 to 86.4)83.3 (70.4 to 91.3)83.3 (69.4 to 91.7)
At Day 1489.6 (77.8 to 95.5)89.8 (78.2 to 95.6)100.0 (92.0 to 100.0)
At Day 2193.0 (81.4 to 97.6)93.8 (83.2 to 97.9)100.0 (91.8 to 100.0)
At Day 2893.8 (83.2 to 97.9)98.0 (89.7 to 99.7)97.7 (88.2 to 99.6)
SecondaryNumber of Participants in Each Clinical Status Category Based on 9-Point Ordinal Scale

Clinical status was based on data collected on the 'Ordinal Scale for Clinical Status and is assessed with the following ordinal scale: 0. Uninfected: no clinical or virological evidence of infection; 1. Ambulatory: no limitation of activities; 2. Ambulatory: limitation of activities; 3. Hospitalized, mild disease: hospitalized, no oxygen therapy; 4. Hospitalized, mild disease: oxygen by mask or nasal prongs; 5. Hospitalized, severe disease: noninvasive ventilation or high-flow oxygen; 6. Hospitalized, severe disease: intubation and mechanical ventilation; 7. Hospitalized, severe disease: ventilation plus additional organ support for example: vasopressors or ECMO; 8. Death.

Time frame:
Baseline, Day 2, Day 3, Day 4, Day 5, Day 7, Day 10, Day 14, Day 21, Day 28, Day 44, Day 60
Reported as:
Count of participants · Participants
Number of Participants in Each Clinical Status Category Based on 9-Point Ordinal Scale
ParticipantsPlaceboM5049 50 Milligram (mg)M5049 100 mg
Participants with Scale 0 at Baseline000
Participants with Scale 1 at Baseline000
Participants with Scale 2 at Baseline000
Participants with Scale 3 at Baseline100
Participants with Scale 4 at Baseline485244
Participants with Scale 5 at Baseline000
Participants with Scale 6 at Baseline000
Participants with Scale 7 at Baseline000
Participants with Scale 8 at Baseline000
Participants with Scale 0 at Day 2000
Participants with Scale 1 at Day 2100
Participants with Scale 2 at Day 2012
Participants with Scale 3 at Day 291213
Participants with Scale 4 at Day 2353930
Participants with Scale 5 at Day 2301
Participants with Scale 6 at Day 2010
Participants with Scale 7 at Day 2000
Participants with Scale 8 at Day 2000
Participants with Scale 0 at Day 3000
Participants with Scale 1 at Day 3221
Participants with Scale 2 at Day 3132
Participants with Scale 3 at Day 312914
Participants with Scale 4 at Day 3293626
Participants with Scale 5 at Day 3401
Participants with Scale 6 at Day 3110
Participants with Scale 7 at Day 3000
Participants with Scale 8 at Day 3000
Participants with Scale 0 at Day 4000
Participants with Scale 1 at Day 4010
Participants with Scale 2 at Day 4010
Participants with Scale 3 at Day 4141611
Participants with Scale 4 at Day 4172221
Participants with Scale 5 at Day 4510
Participants with Scale 6 at Day 4010
Participants with Scale 7 at Day 4100
Participants with Scale 8 at Day 4000
Participants with Scale 0 at Day 5010
Participants with Scale 1 at Day 5966
Participants with Scale 2 at Day 5454
Participants with Scale 3 at Day 5131816
Participants with Scale 4 at Day 5111414
Participants with Scale 5 at Day 5630
Participants with Scale 6 at Day 5010
Participants with Scale 7 at Day 5200
Participants with Scale 8 at Day 5000
Participants with Scale 0 at Day 7011
Participants with Scale 1 at Day 7151615
Participants with Scale 2 at Day 71198
Participants with Scale 3 at Day 7101411
Participants with Scale 4 at Day 7457
Participants with Scale 5 at Day 7520
Participants with Scale 6 at Day 7010
Participants with Scale 7 at Day 7200
Participants with Scale 8 at Day 7000
Participants with Scale 0 at Day 10522
Participants with Scale 1 at Day 10162118
Participants with Scale 2 at Day 10847
Participants with Scale 3 at Day 105107
Participants with Scale 4 at Day 10521
Participants with Scale 5 at Day 10220
Participants with Scale 6 at Day 10010
Participants with Scale 7 at Day 10100
Participants with Scale 8 at Day 10100
Participants with Scale 0 at Day 14556
Participants with Scale 1 at Day 14262523
Participants with Scale 2 at Day 14788
Participants with Scale 3 at Day 14567
Participants with Scale 4 at Day 14230
Participants with Scale 5 at Day 14010
Participants with Scale 6 at Day 14110
Participants with Scale 7 at Day 14000
Participants with Scale 8 at Day 14200
Participants with Scale 0 at Day 21887
Participants with Scale 1 at Day 21223035
Participants with Scale 2 at Day 21971
Participants with Scale 3 at Day 21100
Participants with Scale 4 at Day 21020
Participants with Scale 5 at Day 21000
Participants with Scale 6 at Day 21010
Participants with Scale 7 at Day 21100
Participants with Scale 8 at Day 21200
Participants with Scale 0 at Day 28141115
Participants with Scale 1 at Day 28243524
Participants with Scale 2 at Day 28534
Participants with Scale 3 at Day 28210
Participants with Scale 4 at Day 28101
Participants with Scale 5 at Day 28000
Participants with Scale 6 at Day 28000
Participants with Scale 7 at Day 28000
Participants with Scale 8 at Day 28210
Participants with Scale 0 at Day 44171722
Participants with Scale 1 at Day 44233020
Participants with Scale 2 at Day 44441
Participants with Scale 3 at Day 44200
Participants with Scale 4 at Day 44000
Participants with Scale 5 at Day 44000
Participants with Scale 6 at Day 44000
Participants with Scale 7 at Day 44000
Participants with Scale 8 at Day 44210
Participants with Scale 0 at Day 60181722
Participants with Scale 1 at Day 60243122
Participants with Scale 2 at Day 60321
Participants with Scale 3 at Day 60000
Participants with Scale 4 at Day 60000
Participants with Scale 5 at Day 60000
Participants with Scale 6 at Day 60000
Participants with Scale 7 at Day 60000
Participants with Scale 8 at Day 60210
SecondaryTime to Reach Peripheral Capillary Oxygen Saturation (SpO2) Greater Than or Equal to 94 Percent for at Least 24 Hours in Room Air

SpO2 is an estimate of the amount of oxygen in the blood. It is the percentage of hemoglobin containing oxygen compared to the total amount of hemoglobin in the blood (that is, oxygenated hemoglobin versus oxygenated and non-oxygenated hemoglobin). SpO2 measured by pulse oximetry. The time to SPO2 greater than or equal to (\>=) 94 percent (%) sustained for at least 24 hours in room air is reported in days.

Time frame:
Day 1 through Day 28
Reported as:
Median · Days
Time to Reach Peripheral Capillary Oxygen Saturation (SpO2) Greater Than or Equal to 94 Percent for at Least 24 Hours in Room Air
DaysPlaceboM5049 50 Milligram (mg)M5049 100 mg
Time to Reach Peripheral Capillary Oxygen Saturation (SpO2) Greater Than or Equal to 94 Percent for at Least 24 Hours in Room Air4.7 (2.8 to 6.9)4.8 (3.2 to 5.9)5.0 (3.9 to 9.0)
SecondaryPercentage of Participants With All-Cause Mortality

Percentage of Participants who died for any reason reported.

Time frame:
Day 1 through Day 60
Reported as:
Number · Percentage of participants
Percentage of Participants With All-Cause Mortality
Percentage of participantsPlaceboM5049 50 Milligram (mg)M5049 100 mg
Percentage of Participants With All-Cause Mortality4.1 (1.1 to 13.7)1.9 (0.3 to 9.8)0.0 (0.0 to 7.7)
SecondaryTime to Intensive Care Unit (ICU) Admission

Time to ICU admission was defined as the time from first dose (Day 1) to the date/time of ICU admission, or death, whichever occurs first, in days. Event-free survival function for time to event (ICU admission or death) estimated via Kaplan-Meier method.

Time frame:
Day 1 through Day 28
Reported as:
Median · Days
Time to Intensive Care Unit (ICU) Admission
DaysPlaceboM5049 50 Milligram (mg)M5049 100 mg
Time to Intensive Care Unit (ICU) AdmissionNA (NA to NA)NA (NA to NA)NA (NA to NA)
SecondaryTime to Non-Invasive Mechanical Ventilation

Time to non-invasive mechanical ventilation was defined as the time from first dose (Day 1) to the date/time of clinical status \>= 5, in days. Event-free survival function for time to event (Non-invasive mechanical ventilation or death) estimated via Kaplan-Meier method. Clinical status was based on data collected on the 'Ordinal Scale for Clinical Status and is assessed with the following ordinal scale: 0. Uninfected: no clinical or virological evidence of infection; 1. Ambulatory: no limitation of activities; 2. Ambulatory: limitation of activities; 3. Hospitalized, mild disease: hospitalized, no oxygen therapy; 4. Hospitalized, mild disease: oxygen by mask or nasal prongs; 5. Hospitalized, severe disease: noninvasive ventilation or high-flow oxygen; 6. Hospitalized, severe disease: intubation and mechanical ventilation; 7. Hospitalized, severe disease: ventilation plus additional organ support for example: vasopressors, and ECMO; 8. Death

Time frame:
Day 1 through Day 28
Reported as:
Median · Days
Time to Non-Invasive Mechanical Ventilation
DaysPlaceboM5049 50 Milligram (mg)M5049 100 mg
Time to Non-Invasive Mechanical VentilationNA (NA to NA)NA (NA to NA)NA (NA to NA)
SecondaryTime to Invasive Mechanical Ventilation

Time to invasive mechanical ventilation was defined as the time from first dose (Day 1) to the date/time of clinical status \>= 6, in days. Event-free survival function for time to event (invasive mechanical ventilation or death) estimated via Kaplan-Meier method. Clinical status was based on data collected on the 'Ordinal Scale for Clinical Status and is assessed with the following ordinal scale: 0. Uninfected: no clinical or virological evidence of infection; 1. Ambulatory: no limitation of activities; 2. Ambulatory: limitation of activities; 3. Hospitalized, mild disease: hospitalized, no oxygen therapy; 4. Hospitalized, mild disease: oxygen by mask or nasal prongs; 5. Hospitalized, severe disease: noninvasive ventilation or high-flow oxygen; 6. Hospitalized, severe disease: intubation and mechanical ventilation; 7. Hospitalized, severe disease: ventilation plus additional organ support for example: vasopressors, and ECMO; 8. Death.

Time frame:
Day 1 through Day 28
Reported as:
Median · Days
Time to Invasive Mechanical Ventilation
DaysPlaceboM5049 50 Milligram (mg)M5049 100 mg
Time to Invasive Mechanical VentilationNA (NA to NA)NA (NA to NA)NA (NA to NA)
SecondaryTotal Length of Stay in Intensive Care Unit (ICU)

Total days in the ICU was defined as the sum, for all ICU admissions, of the time from ICU admission to the date of ICU discharge, in days.

Time frame:
Day 1 through Day 60
Reported as:
Median · Days
Total Length of Stay in Intensive Care Unit (ICU)
DaysPlaceboM5049 50 Milligram (mg)M5049 100 mg
Total Length of Stay in Intensive Care Unit (ICU)7.1 (1 to 17)10.2 (3 to 23)3.7 (2 to 6)
SecondaryTotal Length of Hospitalization Stay

Total days in the hospital was defined as the sum, for all hospitalization events, of the time from first dose to the date of hospital discharge in days.

Time frame:
Day 1 through Day 60
Reported as:
Median · Days
Total Length of Hospitalization Stay
DaysPlaceboM5049 50 Milligram (mg)M5049 100 mg
Total Length of Hospitalization Stay7.0 (2 to 41)6.0 (2 to 29)6.0 (2 to 17)
SecondaryTime to Hospital Discharge

The time to hospital discharge, defined as the time from first dose (Day 1) to the date of first hospitalization discharge, in days.

Time frame:
Day 1 through Day 60
Reported as:
Median · Days
Time to Hospital Discharge
DaysPlaceboM5049 50 Milligram (mg)M5049 100 mg
Time to Hospital Discharge5.1 (3.7 to 6.0)5.1 (4.0 to 7.1)4.7 (3.7 to 5.9)
SecondaryPercent Change From Baseline in Inflammatory Biomarkers Over Time

C-Reactive Protein, D-Dimer and Ferritin inflammatory biomarkers were analyzed for this study. Percent Change From Baseline in Inflammatory Biomarkers Over Time were reported here.

Time frame:
Baseline, Day 3, Day7, Day 10, Day 14 and Day 28
Reported as:
Mean · Percent change
Percent Change From Baseline in Inflammatory Biomarkers Over Time
Percent changePlaceboM5049 50 Milligram (mg)M5049 100 mg
Percent change at Day 3 in C-Reactive Protein-0.8 ± 113.5748.2 ± 399.18-45.1 ± 59.64
Percent change at Day 7 in C-Reactive Protein-48.1 ± 69.03-50.4 ± 133.43-74.3 ± 32.19
Percent change at Day 10 in C-Reactive Protein10.5 ± 182.35-58.2 ± 43.93-68.3 ± 81.09
Percent change at Day 14 in C-Reactive Protein-62.1 ± 39.9524.6 ± 543.06-51.2 ± 159.45
Percent change at Day 28 in C-Reactive Protein-62.0 ± 91.47-27.0 ± 253.69-72.4 ± 45.01
Percent change at Day 3 in D-Dimer62.5 ± 150.192008.7 ± 11813.542093.9 ± 11278.04
Percent change at Day 7 in D-Dimer184.5 ± 517.9435.4 ± 197.991922.7 ± 9449.18
Percent change at Day 10 in D-Dimer2004.2 ± 5139.0162.6 ± 202.41171.3 ± 501.83
Percent change at Day 14 in D-Dimer1136.7 ± 6760.100.7 ± 86.6215.1 ± 100.97
Percent change at Day 28 in D-Dimer893.4 ± 4731.82-5.9 ± 61.091371.6 ± 6985.20
Percent change at Day 3 in Ferritin17.8 ± 83.233.4 ± 43.05-7.2 ± 20.63
Percent change at Day 7 in Ferritin11.1 ± 151.34-22.7 ± 40.53-19.8 ± 27.64
Percent change at Day 10 in Ferritin21.4 ± 167.00-25.4 ± 31.52-39.7 ± 25.13
Percent change at Day 14 in Ferritin-29.4 ± 117.71-47.8 ± 31.56-49.9 ± 18.54
Percent change at Day 28 in Ferritin-61.3 ± 35.83-62.3 ± 25.83-63.2 ± 15.71
SecondaryPercent Change From Baseline in Serum Cytokine Biomarkers

Interleukin 6 and Interleukin 8 serum cytokine biomarkers were analyzed. Percent Change From Baseline in Serum Cytokine Biomarkers were reported.

Time frame:
Baseline, Day 3, Day7, Day 14 and Day 28
Reported as:
Mean · Percent change
Percent Change From Baseline in Serum Cytokine Biomarkers
Percent changePlaceboM5049 50 Milligram (mg)M5049 100 mg
Percent change at Day 3 in Interleukin 651.2 ± 257.64-17.8 ± 38.951722.3 ± 10240.47
Percent change at Day 7 in Interleukin 635.2 ± 167.991.1 ± 159.45-25.5 ± 42.41
Percent change at Day 14 in Interleukin 620.2 ± 164.1955.2 ± 476.42275.1 ± 1745.50
Percent change at Day 28 in Interleukin 6-21.0 ± 41.33-27.3 ± 37.78-30.1 ± 36.93
Percent change at Day 3 in Interleukin 842.5 ± 165.562.0 ± 77.66126.6 ± 574.74
Percent change at Day 7 in Interleukin 8923.4 ± 4432.6360.2 ± 253.1228.5 ± 113.48
Percent change at Day 14 in Interleukin 8408.9 ± 1776.8735.4 ± 147.85283.5 ± 1616.08
Percent change at Day 28 in Interleukin 8-4.3 ± 90.29-13.0 ± 59.00-1.8 ± 123.62
SecondaryPercentage of Participants With Relapse

Relapse refers to rehospitalization due to worsening oxygenation, with either a positive result of any respiratory pathogenic nucleic acid test, or worsening lesions on chest imaging.

Time frame:
Day 5 through Day 60
Reported as:
Number · Percentage of participants
Percentage of Participants With Relapse
Percentage of participantsPlaceboM5049 50 Milligram (mg)M5049 100 mg
Percentage of Participants With Relapse0.0 (0.00 to 7.27)0.0 (0.00 to 6.64)0.0 (0.00 to 7.71)
SecondaryPercentage of Participants Who Are Re-Hospitalized

Percentage or participants who are re-hospitalized due to coronavirus disease 2019 (Covid-19) complications were reported.

Time frame:
Day 5 through Day 60
Reported as:
Number · Percentage of participants
Percentage of Participants Who Are Re-Hospitalized
Percentage of participantsPlaceboM5049 50 Milligram (mg)M5049 100 mg
Percentage of Participants Who Are Re-Hospitalized0.0 (0.00 to 7.27)0.0 (0.00 to 6.76)2.2 (0.38 to 11.34)

Adverse events

Collected over Baseline up to Day 60. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo2/49 (4.1%)9/49 (18.4%)12/49 (24.5%)
M5049 50 Milligram (mg)1/54 (1.9%)5/54 (9.3%)15/54 (27.8%)
M5049 100 mg0/46 (0%)1/46 (2.2%)10/46 (21.7%)
Most frequent serious events
Showing 10 of 12
Most frequent serious events
EventPlaceboM5049 50 Milligram (mg)M5049 100 mg
COVID-19Infections and infestations3/494/540/46
SepsisInfections and infestations2/490/540/46
Oxygen saturation decreasedInvestigations2/490/540/46
Pulmonary embolismRespiratory, thoracic and mediastinal disorders0/490/541/46
AnaemiaBlood and lymphatic system disorders1/490/540/46
Gastric ulcerGastrointestinal disorders1/490/540/46
Upper gastrointestinal haemorrhageGastrointestinal disorders1/490/540/46
Clostridium difficile infectionInfections and infestations1/490/540/46
Carpal tunnel syndromeNervous system disorders1/490/540/46
Acute kidney injuryRenal and urinary disorders1/490/540/46
Most frequent other events
Most frequent other events
EventPlaceboM5049 50 Milligram (mg)M5049 100 mg
Alanine aminotransferase increasedInvestigations6/491/541/46
ConstipationGastrointestinal disorders2/496/540/46
HypokalaemiaMetabolism and nutrition disorders1/493/544/46
InsomniaPsychiatric disorders4/491/541/46
DiarrhoeaGastrointestinal disorders0/494/540/46
Sinus bradycardiaCardiac disorders0/491/543/46
RashSkin and subcutaneous tissue disorders1/490/543/46
Transaminases increasedInvestigations1/493/541/46

Baseline characteristics

Safety analysis set included all participants who had received at least one dose of study intervention.

Age, Continuous
Age, Continuous(Years)PlaceboM5049 50 Milligram (mg)M5049 100 mgTotal
Mean48.4 ± 14.0951.0 ± 12.2549.2 ± 12.3549.6 ± 12.87
Sex: Female, Male
Sex: Female, Male(Participants)PlaceboM5049 50 Milligram (mg)M5049 100 mgTotal
Female18191451
Male31353298
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)PlaceboM5049 50 Milligram (mg)M5049 100 mgTotal
Hispanic or Latino29382996
Not Hispanic or Latino20151550
Unknown or Not Reported0123
Race (NIH/OMB)
Race (NIH/OMB)(Participants)PlaceboM5049 50 Milligram (mg)M5049 100 mgTotal
American Indian or Alaska Native0000
Asian13161241
Native Hawaiian or Other Pacific Islander1001
Black or African American37414
White22202567
More than one race67013
Unknown or Not Reported44513
08

Study locations

21 sites
  • LAC-USC Medical Center
    Los Angeles, California 90033, United States
  • Sharp Chula Vista Medical Center
    San Diego, California 92123, United States
  • Henry Ford Medical Center
    Detroit, Michigan 48202, United States
  • Holy Name Hospital - Dept of Multiple Sclerosis Comp Care Center
    Teaneck, New Jersey 07666, United States
  • Christus Spohn Hospital Corpus Christi-Memorial
    Corpus Christi, Texas 78404, United States
  • Santa Casa de Misericórdia de Belo Horizonte
    Belo Horizonte, Brazil
  • Hospital Dia do Pulmão
    Blumenau, Brazil
  • Hospital São José - Sociedade Literária e Caritativa Santo Agostinho
    Criciúma, Brazil
  • Hospital de Clínicas de Porto Alegre
    Porto Alegre, Brazil
  • HMCG - Hospital e Maternidade Dr. Christovão da Gama
    Santo André, Brazil
  • Pesquisare
    Santo André, Brazil
  • Hospital Leforte Morumbi
    Sao Paulo, Brazil
  • Hospital Alemão Oswaldo Cruz
    São Paulo, Brazil
  • Hospital Bandeirantes / Hospital Leforte Liberdade
    São Paulo, Brazil
  • Instituto de Infectologia Emílio Ribas
    São Paulo, Brazil
  • Manila Doctors Hospital
    Manila, Philippines
  • Medical Center Manila - Medicine
    Manila, Philippines
  • East Avenue Medical Center
    Quezon City, Philippines
  • Lung Center of the Philippines - Medicine
    Quezon, Philippines
  • Quirino Memorial Medical Center
    Quezon, Philippines
  • Veterans Memorial Medical Center
    Quezon, Philippines
09

References and documents

Publications

  • Klopp-Schulze L, Shaw JV, Dong JQ, Khandelwal A, Vazquez-Mateo C, Goteti K. Applying Modeling and Simulations for Rational Dose Selection of Novel Toll-Like Receptor 7/8 Inhibitor Enpatoran for Indications of High Medical Need. Clin Pharmacol Ther. 2022 Aug;112(2):297-306. doi: 10.1002/cpt.2606. Epub 2022 May 21. PubMed 35390178 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — We are committed to enhancing public health through responsible sharing of clinical trial data. Following approval of a new product or a new indication for an approved product in both the US and European Union, the study sponsor and/or its affiliated companies will share study protocols, anonymized patient data and study level data, and redacted clinical study reports with qualified scientific and medical researchers, upon request, as necessary for conducting legitimate research. Further information on how to request data can be found on our website bit.ly/IPD21

Supporting information: Study protocol, Statistical analysis plan, Clinical study report, Analytic code

Time frame: Within six months after the approval of a new product or a new indication for an approved product in both the United States and the European Union

Access criteria: Qualified scientific and medical researchers can request the data. Such requests must be submitted in writing to the company's portal and will be internally reviewed regarding criteria for researchers' qualification and legitimacy of the research proposal.

Data sharing details ↗ · bit.ly

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jul 2020 to primary completion in Aug 2021, 12 months.

Results were first posted in Jun 2022, 9 months after primary completion.

Of 224 industry-sponsored phase 2 interventional studies under COVID-19, half reached primary completion within 8 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 13. This study's 12 months is above that.

Counting every sponsor, half of 583 studies reached it within 9 months; a quarter within 5 and three quarters within 16.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 25, 2020
First posted
Jun 26, 2020
StartActual
Jul 29, 2020
Primary completionActual
Aug 16, 2021
CompletionActual
Aug 16, 2021
Results first posted
Jun 6, 2022
Last update
Jun 6, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 6, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04448756
Responsible party
Sponsor
First posted
Jun 26, 2020
Start date
Jul 29, 2020
Primary completion
Aug 16, 2021
Completion
Aug 16, 2021
Results posted
Jun 6, 2022
Last update
Jun 6, 2022

Study contacts

Medical Responsible
study director · Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Enpatoran

Start the discussion